Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers

Natee Jearawiriyapaisarn, Hong M. Moulton, Peter Sazani, Ryszard Kole, Monte Willis

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Aims The cardiomyopathy found in Duchenne muscular dystrophy (DMD) is responsible for death due to heart failure in ∼30 of patients and additionally contributes to many DMD morbidities. Strategies to bypass DMD-causing mutations to allow an increase in body-wide dystrophin have proved promising, but increasing cardiac dystrophin continues to be challenging. The purpose of this study was to determine if therapeutic restoration of cardiac dystrophin improved the significant cardiac hypertrophy and diastolic dysfunction identified in X-linked muscular dystrophy (mdx) dystrophin-null mouse due to a truncation mutation over time after treatment.Methods and results Mice lacking dystrophin due to a truncation mutation (mdx) were given an arginine-rich, cell-penetrating, peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) that delivered a splice-switching oligonucleotide-mediated exon skipping therapy to restore dystrophin in mdx mice before the development of detectable cardiomyopathy. PPMO successfully restored cardiac dystrophin expression, preserved cardiac sarcolemma integrity, and prevented the development of cardiac pathology that develops in mdx-null mice over time. By echocardiography and Doppler analysis of the mitral valve, we identified that PPMO treatment of mdx mice prevented the cardiac hypertrophy and diastolic dysfunction identified in sham-treated, age-matched mdx mice, characteristic of DMD patients early in the disease process, in as little as 5-6 weeks after the initiation of treatment. Surprisingly, despite the short-term replacement of cardiac dystrophin (<1 present after 12 weeks by immunodetection), PPMO therapy also provided a durable cardiac improvement in cardiac hypertrophy and diastolic dysfunction for up to 7 months after the initiation of treatment.Conclusion These results demonstrate for the first time that PPMO-mediated exon skipping therapy early in the course of DMD may effectively prevent or slow down associated cardiac hypertrophy and diastolic dysfunction with significant long-term impact.

Original languageEnglish (US)
Pages (from-to)444-453
Number of pages10
JournalCardiovascular Research
Volume85
Issue number3
DOIs
StatePublished - Feb 1 2010
Externally publishedYes

Fingerprint

Morpholinos
Dystrophin
Cardiomyopathies
Duchenne Muscular Dystrophy
Inbred mdx Mouse
Peptides
Cardiomegaly
Therapeutics
Mutation
Exons
Cell-Penetrating Peptides
Sarcolemma
Muscular Dystrophies
Doppler Echocardiography
Mitral Valve
Oligonucleotides
Arginine
Heart Failure
Pathology
Morbidity

Keywords

  • Alternative RNA splicing
  • Cardiomyopathy
  • Duchenne muscular dystrophy
  • Exon skipping
  • Morpholino
  • Oligomers
  • Therapy

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. / Jearawiriyapaisarn, Natee; Moulton, Hong M.; Sazani, Peter; Kole, Ryszard; Willis, Monte.

In: Cardiovascular Research, Vol. 85, No. 3, 01.02.2010, p. 444-453.

Research output: Contribution to journalArticle

Jearawiriyapaisarn, Natee ; Moulton, Hong M. ; Sazani, Peter ; Kole, Ryszard ; Willis, Monte. / Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. In: Cardiovascular Research. 2010 ; Vol. 85, No. 3. pp. 444-453.
@article{66c61ffe263b43abbcfb049bd1ca346f,
title = "Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers",
abstract = "Aims The cardiomyopathy found in Duchenne muscular dystrophy (DMD) is responsible for death due to heart failure in ∼30 of patients and additionally contributes to many DMD morbidities. Strategies to bypass DMD-causing mutations to allow an increase in body-wide dystrophin have proved promising, but increasing cardiac dystrophin continues to be challenging. The purpose of this study was to determine if therapeutic restoration of cardiac dystrophin improved the significant cardiac hypertrophy and diastolic dysfunction identified in X-linked muscular dystrophy (mdx) dystrophin-null mouse due to a truncation mutation over time after treatment.Methods and results Mice lacking dystrophin due to a truncation mutation (mdx) were given an arginine-rich, cell-penetrating, peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) that delivered a splice-switching oligonucleotide-mediated exon skipping therapy to restore dystrophin in mdx mice before the development of detectable cardiomyopathy. PPMO successfully restored cardiac dystrophin expression, preserved cardiac sarcolemma integrity, and prevented the development of cardiac pathology that develops in mdx-null mice over time. By echocardiography and Doppler analysis of the mitral valve, we identified that PPMO treatment of mdx mice prevented the cardiac hypertrophy and diastolic dysfunction identified in sham-treated, age-matched mdx mice, characteristic of DMD patients early in the disease process, in as little as 5-6 weeks after the initiation of treatment. Surprisingly, despite the short-term replacement of cardiac dystrophin (<1 present after 12 weeks by immunodetection), PPMO therapy also provided a durable cardiac improvement in cardiac hypertrophy and diastolic dysfunction for up to 7 months after the initiation of treatment.Conclusion These results demonstrate for the first time that PPMO-mediated exon skipping therapy early in the course of DMD may effectively prevent or slow down associated cardiac hypertrophy and diastolic dysfunction with significant long-term impact.",
keywords = "Alternative RNA splicing, Cardiomyopathy, Duchenne muscular dystrophy, Exon skipping, Morpholino, Oligomers, Therapy",
author = "Natee Jearawiriyapaisarn and Moulton, {Hong M.} and Peter Sazani and Ryszard Kole and Monte Willis",
year = "2010",
month = "2",
day = "1",
doi = "10.1093/cvr/cvp335",
language = "English (US)",
volume = "85",
pages = "444--453",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers

AU - Jearawiriyapaisarn, Natee

AU - Moulton, Hong M.

AU - Sazani, Peter

AU - Kole, Ryszard

AU - Willis, Monte

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Aims The cardiomyopathy found in Duchenne muscular dystrophy (DMD) is responsible for death due to heart failure in ∼30 of patients and additionally contributes to many DMD morbidities. Strategies to bypass DMD-causing mutations to allow an increase in body-wide dystrophin have proved promising, but increasing cardiac dystrophin continues to be challenging. The purpose of this study was to determine if therapeutic restoration of cardiac dystrophin improved the significant cardiac hypertrophy and diastolic dysfunction identified in X-linked muscular dystrophy (mdx) dystrophin-null mouse due to a truncation mutation over time after treatment.Methods and results Mice lacking dystrophin due to a truncation mutation (mdx) were given an arginine-rich, cell-penetrating, peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) that delivered a splice-switching oligonucleotide-mediated exon skipping therapy to restore dystrophin in mdx mice before the development of detectable cardiomyopathy. PPMO successfully restored cardiac dystrophin expression, preserved cardiac sarcolemma integrity, and prevented the development of cardiac pathology that develops in mdx-null mice over time. By echocardiography and Doppler analysis of the mitral valve, we identified that PPMO treatment of mdx mice prevented the cardiac hypertrophy and diastolic dysfunction identified in sham-treated, age-matched mdx mice, characteristic of DMD patients early in the disease process, in as little as 5-6 weeks after the initiation of treatment. Surprisingly, despite the short-term replacement of cardiac dystrophin (<1 present after 12 weeks by immunodetection), PPMO therapy also provided a durable cardiac improvement in cardiac hypertrophy and diastolic dysfunction for up to 7 months after the initiation of treatment.Conclusion These results demonstrate for the first time that PPMO-mediated exon skipping therapy early in the course of DMD may effectively prevent or slow down associated cardiac hypertrophy and diastolic dysfunction with significant long-term impact.

AB - Aims The cardiomyopathy found in Duchenne muscular dystrophy (DMD) is responsible for death due to heart failure in ∼30 of patients and additionally contributes to many DMD morbidities. Strategies to bypass DMD-causing mutations to allow an increase in body-wide dystrophin have proved promising, but increasing cardiac dystrophin continues to be challenging. The purpose of this study was to determine if therapeutic restoration of cardiac dystrophin improved the significant cardiac hypertrophy and diastolic dysfunction identified in X-linked muscular dystrophy (mdx) dystrophin-null mouse due to a truncation mutation over time after treatment.Methods and results Mice lacking dystrophin due to a truncation mutation (mdx) were given an arginine-rich, cell-penetrating, peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) that delivered a splice-switching oligonucleotide-mediated exon skipping therapy to restore dystrophin in mdx mice before the development of detectable cardiomyopathy. PPMO successfully restored cardiac dystrophin expression, preserved cardiac sarcolemma integrity, and prevented the development of cardiac pathology that develops in mdx-null mice over time. By echocardiography and Doppler analysis of the mitral valve, we identified that PPMO treatment of mdx mice prevented the cardiac hypertrophy and diastolic dysfunction identified in sham-treated, age-matched mdx mice, characteristic of DMD patients early in the disease process, in as little as 5-6 weeks after the initiation of treatment. Surprisingly, despite the short-term replacement of cardiac dystrophin (<1 present after 12 weeks by immunodetection), PPMO therapy also provided a durable cardiac improvement in cardiac hypertrophy and diastolic dysfunction for up to 7 months after the initiation of treatment.Conclusion These results demonstrate for the first time that PPMO-mediated exon skipping therapy early in the course of DMD may effectively prevent or slow down associated cardiac hypertrophy and diastolic dysfunction with significant long-term impact.

KW - Alternative RNA splicing

KW - Cardiomyopathy

KW - Duchenne muscular dystrophy

KW - Exon skipping

KW - Morpholino

KW - Oligomers

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=74249109987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74249109987&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvp335

DO - 10.1093/cvr/cvp335

M3 - Article

C2 - 19815563

AN - SCOPUS:74249109987

VL - 85

SP - 444

EP - 453

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 3

ER -